Clinica BavieraXMAD:CBAV +4.51%100 PS Ratio is 3.13 as of Jul. 02, 2026, which is 73% above its 10-year median of 1.81. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.34 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Clinica Baviera ranks worse than 54% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Clinica Baviera's share price is €60.20.
Clinica Baviera's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €19.26. Hence, Clinica Baviera's PS Ratio for today is 3.13.
Warning Sign:
Clinica Baviera SA stock PS Ratio (=2.87) is close to 10-year high of 3.08.
The historical rank and industry rank for Clinica Baviera's PS Ratio or its related term are showing as below:
XMAD:CBAV'
s PS Ratio Range Over the Past 10 Years
Min: 1.11 Med: 1.81 Max: 3.12
Current: 3.12
During the past 13 years, Clinica Baviera's highest PS Ratio was 3.12. The lowest was 1.11. And the median was 1.81.
XMAD:CBAV's PS Ratio is ranked worse than 54% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.805
vs XMAD:CBAV: 3.12
Clinica Baviera SA has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Clinica Baviera was 11.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 15.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 18.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 14.20% per year.
During the past 13 years, Clinica Baviera's highest 3-Year average Revenue per Share Growth Rate was 26.30% per year. The lowest was -58.60% per year. And the median was 6.80% per year.
Back to Basics: PS Ratio
Clinica Baviera (XMAD:CBAV) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Clinica Baviera PS Ratio Related Terms
Clinica Baviera PS Ratio Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Clinica Baviera's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's PS Ratio distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Clinica Baviera's Share Price of today is €60.20. Clinica Baviera's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Clinica Baviera (XMAD:CBAV) has a PS Ratio of 3.13 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Clinica Baviera and its competitors. This is 73% above median its historical median of 1.81. Over the past decade, Clinica Baviera's PS Ratio has ranged from 1.11 to 3.12. According to the industry distribution chart, Clinica Baviera ranks #108 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 54%.
Is Clinica Baviera's PS Ratio too high?
Clinica Baviera's current PS Ratio of 3.13 is 73% above median its 10-year median of 1.81. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 3.12. The Medical Diagnostics & Research industry median PS Ratio is 2.81. Clinica Baviera's value of 3.13 is 11.6% above this industry median. Based on the distribution chart, Clinica Baviera ranks #108 out of 200 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #108 out of 200 companies for PS Ratio. This places Clinica Baviera in the lower half of its industry. The industry median PS Ratio is 2.81. Clinica Baviera's value of 3.13 is 11.6% above this benchmark. Historically, Clinica Baviera's own PS Ratio has ranged from 1.11 to 3.12 over the past decade. While the company's 10-year median is 1.81 vs. the industry median of 2.81, Clinica Baviera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.81, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current PS Ratio of 3.13 is 11.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current PS Ratio is 3.13, which is 73% above median its own 10-year median of 1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.34, compared to a current price of €60.20 — trading 45.6% above its estimated fair value. The current PS Ratio is 3.13, which is 73% above median its 10-year median of 1.81 and 11.6% above the Medical Diagnostics & Research industry median of 2.81. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current PS Ratio is 3.13 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €60.20 is trading 45.6% above its estimated GF Value™ of €41.34.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
PS Ratio: 3.13 (73% above median its 10-year median of 1.81)
GF Value™: €41.34 vs. price of €60.20 (45.6% above fair value)
Industry Position: 11.6% above the Medical Diagnostics & Research median (#108 of 200)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
